These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 14474513)

  • 21. [Azotemic nephritis during antimony therapy of a case of infantile visceral leishmaniasis].
    CHARLAS R; BENABADJI A
    Maroc Med; 1962 Dec; 41():1180-2. PubMed ID: 14020224
    [No Abstract]   [Full Text] [Related]  

  • 22. A new sodium antimony gluconate for the treatment of kala-azar.
    DASTIDAR SK
    J Indian Med Assoc; 1945 Sep; 14():298. PubMed ID: 21003768
    [No Abstract]   [Full Text] [Related]  

  • 23. [LEISHMANIASIS AS ENCOUNTERED IN FRANCE. CLINICAL AND THERAPEUTIC ASPECTS].
    SCHNEIDER J
    Rev Prat; 1964 Mar; 14():1149-63. PubMed ID: 14146424
    [No Abstract]   [Full Text] [Related]  

  • 24. [New observations on the treatment of cutaneous leishmaniasis by antimon-detoxin].
    PESSOA SB; VILLELA F
    Rev Paul Med; 1946 Mar; 28(3):201. PubMed ID: 20281154
    [No Abstract]   [Full Text] [Related]  

  • 25. [Our experience in the treatment of kala-azar].
    de YTURRIAGA E; GONZALEZ BOTELLA S
    Acta Pediatr Esp; 1950 May; 8(89):569-76. PubMed ID: 15418997
    [No Abstract]   [Full Text] [Related]  

  • 26. [Micromethod in determination of antimony in blood and urine in visceral leishmaniasis during solusurmin therapy].
    LAPIN LN
    Vopr Med Khim; 1956; 2(4):309-15. PubMed ID: 13392574
    [No Abstract]   [Full Text] [Related]  

  • 27. Treatment of post-kala-azar dermal leishmaniasis with methyl glucamine antimoniate.
    SEN GUPTA PC; BHATTACHARYYA B; DAS AK; SANYAL NN
    J Trop Med Hyg; 1952 Sep; 55(9):205-8. PubMed ID: 13011855
    [No Abstract]   [Full Text] [Related]  

  • 28. [A case report of visceral leishmaniasis].
    Popov G; Andreeva N; Georgiev A; Kuzmanova E
    Vutr Boles; 1991; 30(2):121-5. PubMed ID: 1654012
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Cutaneous leishmaniasis: ulcerous, lupoid, verruciform of zoniform disposition: rapid recovery due to glucatime].
    LAUGIER P; LEVILLAIN R; PAGEAUT G; LENYS R; BIA M
    Bull Soc Fr Dermatol Syphiligr; 1959; 5():822-4. PubMed ID: 13848532
    [No Abstract]   [Full Text] [Related]  

  • 30. Immunochemotherapy of visceral leishmaniasis: a pilot trial of sequential treatment with recombinant interferon-gamma and pentavalent antimony.
    Harms G; Zwingenberger K; Sandkamp B; Omena S; Pedrosa C; Richter J; Rosenkaimer F; Feldmeier H; Bienzle U
    J Interferon Res; 1993 Feb; 13(1):39-41. PubMed ID: 8454909
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Visceral leishmaniasis: a possible diagnosis in Belgium].
    Desmyttere S; Hachimi-Idrissi S; Otten J
    Tijdschr Kindergeneeskd; 1993 Oct; 61(5):182-5. PubMed ID: 8266313
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Behavior of antibodies (titrated by means of the immunofluorescence test) in visceral leishmaniasis treated by antimony therapy].
    Cascio G
    Pediatria (Napoli); 1970 Jul; 78(3):497-504. PubMed ID: 4920029
    [No Abstract]   [Full Text] [Related]  

  • 33. [Antimony resistance in the treatment of visceral leishmaniasis].
    MIRZOIAN NA
    Med Parazitol (Mosk); 1957; 26(3):277-80. PubMed ID: 13482777
    [No Abstract]   [Full Text] [Related]  

  • 34. THE HUMAN TRYPANOSOMATIDAE. III. LEISHMANIASIS: KALA-AZAR.
    CAHILL KM
    N Y State J Med; 1963 Dec; 63():3405-9. PubMed ID: 14083434
    [No Abstract]   [Full Text] [Related]  

  • 35. [Antimony content of the thyroid of man and animals undergoing visceral leishmaniasis treatment with the organic compound of antimony, stibogluconate sodium].
    Fuzaĭlov IuM
    Med Parazitol (Mosk); 1982; 51(1):62-5. PubMed ID: 6278277
    [No Abstract]   [Full Text] [Related]  

  • 36. [Treatment of cutaneous leishmaniasis with methylglucamine antimoniate (2.168 R. P.)].
    RAGU J; SCHNEIDER J
    Ann Dermatol Syphiligr (Paris); 1947 Feb; 7(2):38. PubMed ID: 20253292
    [No Abstract]   [Full Text] [Related]  

  • 37. [About stibio-intolerance and stibio-resistance in the treatment of internal leishmaniasis].
    MURANO G
    Prog Med (Napoli); 1945 Jan; 1():156-60. PubMed ID: 21013812
    [No Abstract]   [Full Text] [Related]  

  • 38. The treatment of visceral leishmaniasis: safety and efficacy.
    Jha RK; Sah AK; Shah DK; Sah P
    JNMA J Nepal Med Assoc; 2013; 52(192):645-51. PubMed ID: 25327244
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Agranulocytosis in visceral leishmaniasis treated with glucantime].
    Bourée P; Dulac O
    Arch Fr Pediatr; 1977; 34(7):659-62. PubMed ID: 931516
    [TBL] [Abstract][Full Text] [Related]  

  • 40. KALA-AZAR IN WISCONSIN, CASE REPORT.
    WELSH EC; KANIN HJ
    Am J Gastroenterol; 1963 Dec; 40():615-9. PubMed ID: 14099445
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.